Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

226 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Metabolic management after sustained virologic response in elderly patients with hepatitis C virus: A multicenter study.
Sano T, Amano K, Ide T, Isoda H, Honma Y, Morita Y, Yano Y, Nakamura H, Itano S, Miyajima I, Shirachi M, Kuwahara R, Ohno M, Kawaguchi T, Tsutsumi T, Nakano D, Arinaga-Hino T, Kawaguchi M, Eguchi Y, Torimura T, Takahashi H, Harada M, Kawaguchi T; SAKS Study Group. Sano T, et al. Among authors: kuwahara r. Hepatol Res. 2024 Apr;54(4):326-335. doi: 10.1111/hepr.13993. Epub 2023 Nov 28. Hepatol Res. 2024. PMID: 37975277
A combination of hepatic encephalopathy and body mass index was associated with the point of no return for improving liver functional reserve after sofosbuvir/velpatasvir treatment in patients with hepatitis C virus-related decompensated cirrhosis.
Sano T, Amano K, Ide T, Yokoyama K, Noguchi K, Nakamura H, Isoda H, Ohno M, Shirachi M, Morita Y, Yano Y, Sumie S, Kawaguchi T, Kuwahara R, Arinaga-Hino T, Takahashi H, Shakado S, Hirai F, Kawaguchi T. Sano T, et al. Among authors: kuwahara r. Hepatol Res. 2023 Jan;53(1):26-34. doi: 10.1111/hepr.13837. Epub 2022 Sep 20. Hepatol Res. 2023. PMID: 36066400
Evaluation of Resistance-Associated Substitutions in NS5A Using Direct Sequence and Cycleave Method and Treatment Outcome with Daclatasvir and Asunaprevir for Chronic Hepatitis C Genotype 1.
Ide T, Eguchi Y, Harada M, Ishii K, Morita M, Morita Y, Sugiyama G, Fukushima H, Yano Y, Noguchi K, Nakamura H, Hisatomi J, Kumemura H, Shirachi M, Iwane S, Okada M, Honma Y, Arinaga-Hino T, Miyajima I, Ogata K, Kuwahara R, Amano K, Kawaguchi T, Kuromatsu R, Torimura T; DAAs Multicenter Study Group. Ide T, et al. Among authors: kuwahara r. PLoS One. 2016 Sep 29;11(9):e0163884. doi: 10.1371/journal.pone.0163884. eCollection 2016. PLoS One. 2016. PMID: 27684567 Free PMC article.
Marked accumulation of fluorodeoxyglucose and inflammatory cells expressing glucose transporter-3 in immunoglobulin G4-related autoimmune hepatitis.
Araki T, Arinaga-Hino T, Koga H, Akiba J, Ide T, Okabe Y, Kuwahara R, Amano K, Yasumoto M, Kawaguchi T, Sano T, Kondou R, Kurata S, Mitsuyama K, Torimura T. Araki T, et al. Among authors: kuwahara r. Hepatol Res. 2018 Oct;48(11):937-944. doi: 10.1111/hepr.13188. Epub 2018 Jun 4. Hepatol Res. 2018. PMID: 29737040
Hepatitis C Virus Elimination Using Direct Acting Antivirals after the Radical Cure of Hepatocellular Carcinoma Suppresses the Recurrence of the Cancer.
Kuromatsu R, Ide T, Okamura S, Noda Y, Kamachi N, Nakano M, Shirono T, Shimose S, Iwamoto H, Kuwahara R, Arinaga-Hino T, Niizeki T, Zaizen Y, Takaki H, Shirachi M, Koga H, Torimura T. Kuromatsu R, et al. Among authors: kuwahara r. Cancers (Basel). 2022 May 4;14(9):2295. doi: 10.3390/cancers14092295. Cancers (Basel). 2022. PMID: 35565424 Free PMC article.
226 results